Used for the treatment of infections caused by aerobic pathogens susceptible to Ceftriaxone.
Lower respiratory tract infections, skin and skin structure infections, urinary tract infections, gonorrhoea (cervical, urethral & rectal), bacterial septicaemia, bone and joint infections, meningitis, surgical prophylaxis etc.
- Ceftriaxone is a semisynthetic broad spectrum cephalosporin antibiotic with bactericidal activity against Gram negative and Gram positive bacteria (including those with beta-lactamases)
Ceftriaxone is usually active against the following pathogens:
- Gram negative anaerobes: E Aerogenes, E Cloacae, E Coli, H Influenzae (including ampicillin resistant strains), Klebsiella SP, N Gonorrhoea (including penicillinase & non penicillinase producing strains), N Meningitis, P Mirabilis, P Vulgaris, M Morganii, S Marcescens, P Aeruginosa (other Pseduomonas SP are usually resistant). Gram positive aerobes: S Aureus (including penicillinase producing strains), S Epidermis (methicillin resistant staphylococci are resistant to cephalosporins, including ceftriaxone), Streptococci SP (most species of group D Streptococci are resistant, including S Faecalis & S Faecium).
- Ceftriaxone is poorly absorbed from the gastrointestinal tract
- Following intramuscular administration, peak plasma drug levels are achieved within 2-3 hours
- 33-67% of a dose is excreted as unchanged ceftriaxone in the urine
- The drug is also secreted in the bile and inactive metabolites are also found in the faeces
- In healthy subjects, elimination half lives range from 5.8-8.7 hours in adults, 4.6 hours in children, 7.2-19 hours in neonatals and 4.0-6.6 hours in infants.